Oryzon will participate at the 14th International Conference on Alzheimer’s Drug Discovery
Oryzon announced today that Dr. Tamara Maes will present the latest advances of its LSD1 program inneurodegenerative disorders at the 14th International Conference on Alzheimer’s Drug Discovery: on September 9-10, 2013 at the Hyatt Regency in Jersey City, NJ.
Oryzon’s will give an oral presentation entitled “LSD1/MAOB Inhibitors as Disease Modifying Drugs for Alzheimer’s Disease” within the Neuroprotection and Synaptic Plasticitysession from 12:00 on Monday. September 9, 2013. Lysine specific demethylase 1 (LSD1, KDM1A), is an epigenetic modulator able that regulates gene expression by demethylating histones. LSD1 forms part of protein complexes involved in transcriptional regulation, and mis-regulation of these transcriptional complexes may result in disease.